A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer

Journal of Controlled Release

Volumn 267, Issue , 2017, Pages 191-202

  Vogus, Douglas R ^a   Evans, Michael A ^b   Pusuluri, Anusha ^a   Barajas, Alexandra ^a   Zhang, Mengwen ^a   Krishnan, Vinu ^a   Nowak, Maksymilian ^a   Menegatti, Stefano ^b   Helgeson, Matthew E ^a   Squires, Todd M ^a   Mitragotri, Samir ^a,b  

^a University of California   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Doxorubcin; Drug combinations; Gemcitabine; Polymer drug conjugates; Synergy

Indexed keywords

CHEMOTHERAPY; DISEASES; DRUG DOSAGE; FUNCTIONAL POLYMERS; HYALURONIC ACID; ORGANIC ACIDS; TARGETED DRUG DELIVERY; TUMORS;

BREAST CANCER; DOXORUBCIN; DRUG COMBINATIONS; GEMCITABINE; POLYMER DRUGS; SYNERGY;

CONTROLLED DRUG DELIVERY;

3',5' O BIS(TERT BUTOXYCARBONYL)GEMCITABINE; 4 GLYCL GEMCITABINE; 4 LEVO VALYL GEMCITABINE; DOXORUBICIN; DRUG CARRIER; GEMCITABINE; HYALURONIC ACID; POLYMER; PRODRUG; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE;

4T1 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG POTENTIATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HYDROLYSIS KINETICS; IC50; IN VITRO STUDY; IN VIVO STUDY; MDA-MB-231 CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; DRUG RELEASE; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; DRUG LIBERATION; DRUG SYNERGISM; HUMANS; HYALURONIC ACID; MICE; MICE, INBRED BALB C; PRODRUGS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85028596826     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2017.08.016     Document Type: Article

References (61)

1. Devita, V.T., Young, R.C., Canellos, G.P., Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 35 (1975), 98–110, 10.1002/1097-0142(197501)35:1<98::AID-CNCR2820350115>3.0.CO;2-B.
2. Tkaczuk, K.H.R., Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer. Clin. Ther. 31:Pt 2 (2009), 2273–2289, 10.1016/j.clinthera.2009.11.011.
3. Carrick, S., Parker, S., Thornton, C.E., Ghersi, D., Simes, J., Wilcken, N., Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst. Rev., 2009, 10.1002/14651858.CD003372.pub3.
4. Chou, T., Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58:3 (2006), 621–681.
5. Oliveras-Ferraros, C., Vazquez-Martin, A., Colomer, R., De Llorens, R., Brunet, J., Menendez, J.A., Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling. Int. J. Oncol. 32 (2008), 113–120.
6. Chou, T.C., Otter, G.M., Sirotnak, F.M., Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemother. Pharmacol. 37 (1996), 222–228.
7. Lee, M.J., Ye, A.S., Gardino, A.K., Heijink, A.M., Sorger, P.K., MacBeath, G., Yaffe, M.B., Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149 (2012), 780–794, 10.1016/j.cell.2012.03.031.
8. Zoli, W., Ricotti, L., Barzanti, F., Dal Susino, M., Frassineti, G.L., Milandri, C., Casadei Giunchi, D., Amadori, D., Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int. J. Cancer. 80 (1999), 413–416.
9. Núñez, C., Capelo, J.L., Igrejas, G., Alfonso, A., Botana, L.M., Lodeiro, C., An overview of the effective combination therapies for the treatment of breast cancer. Biomaterials, 2016, 10.1016/j.biomaterials.2016.04.027.
10. Hu, Q., Sun, W., Wang, C., Gu, Z., Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv. Drug Deliv. Rev. 98 (2016), 19–34, 10.1016/j.addr.2015.10.022.
11. Tai, W., Mo, R., Lu, Y., Jiang, T., Gu, Z., Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugs. Biomaterials 35 (2014), 7194–7203, 10.1016/j.biomaterials.2014.05.004.
12. Camacho, K.M., Menegatti, S., Vogus, D.R., Pusuluri, A., Fuchs, Z., Jarvis, M., Zakrewsky, M., Evans, M.A., Chen, R., Mitragotri, S., DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy. J. Control. Release 229 (2016), 154–162, 10.1016/j.jconrel.2016.03.027.
13. Tardi, P., Johnstone, S., Harasym, N., Xie, S., Harasym, T., Zisman, N., Harvie, P., Bermudes, D., Mayer, L., In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk. Res. 33 (2009), 129–139, 10.1016/j.leukres.2008.06.028.
14. Meng, H., Wang, M., Liu, H., Liu, X., Situ, A., Wu, B., Ji, Z., Hyun Chang, C., Nel, A.E., Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice. ACS Nano 9 (2015), 3540–3557, 10.1021/acsnano.5b00510.
15. Morton, S.W., Lee, M.J., Deng, Z.J., Dreaden, E.C., Siouve, E., Shopsowitz, K.E., Shah, N.J., Yaffe, M.B., Hammond, P.T., Mcmaster, M.L., Kristinsson, S.Y., Turesson, I., Bjorkholm, M., Landgren, O., Morton, S.W., Lee, M.J., Deng, Z.J., Dreaden, E.C., Siouve, E., Shopsowitz, K.E., Shah, N.J., Yaffe, M.B., Hammond, P.T., A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci. Signal., 7, 2014, ra44, 10.1126/scisignal.2005261.
16. Díez, P., Sánchez, A., de la Torre, C., Gamella, M., Martínez-Ruíz, P., Aznar, E., Martínez-Máñez, R., Pingarrón, J.M., Villalonga, R., Neoglycoenzyme-gated mesoporous silica nanoparticles: toward the design of nanodevices for pulsatile programmed sequential delivery. ACS Appl. Mater. Interfaces 8 (2016), 7657–7665, 10.1021/acsami.5b12645.
17. Fan, L., Zhang, Y., Wang, F., Yang, Q., Tan, J., Renata, G., Wu, H., Song, C., Jin, B., Multifunctional all-in-one drug delivery systems for tumor targeting and sequential release of three different anti-tumor drugs. Biomaterials, 2015, 10.1016/j.biomaterials.2015.10.069.
18. Julka, P.K., Chacko, R.T., Nag, S., Parshad, R., Nair, A., Oh, D.S., Hu, Z., Koppiker, C.B., Nair, S., Dawar, R., Dhindsa, N., Miller, I.D., Ma, D., Lin, B., Perou, C.M., Awasthy, B., A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. Br. J. Cancer 98 (2008), 1327–1335, 10.1038/sj.bjc.6604322.
19. Julka, P.K., Chacko, R.T., Nag, S., Parshad, R., Nair, A., Koppiker, C.B., Xue, F.C.R., Barraclough, H., Dhindsa, N., Seth, A., Majumdar, A., Puri, T., A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up. Breast Cancer 20 (2013), 357–362, 10.1007/s12282-012-0343-4.
20. Passardi, A., Massa, I., Zoli, W., Gianni, L., Milandri, C., Zumaglini, F., Nanni, O., Maltoni, R., Frassineti, G.L., Amadori, D., Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience. BMC Cancer, 6, 2006, 76, 10.1186/1471-2407-6-76.
21. Perez-Manga, G., Lluch, A., Alba, E., Moreno-Nogueira, J.A., Palomero, M., Garcia-Conde, J., Khayat, D., Rivelles, N., Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. J. Clin. Oncol. 18 (2000), 2545–2552, 10.1200/JCO.2000.18.13.2545.
22. Yang, T.S., Wang, C.H., Hsieh, R.K., Chen, J.S., Fung, M.C., Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: A phase I-II trial. Ann. Oncol. 13 (2002), 1771–1778, 10.1093/annonc/mdf303.
23. Rivera, E., Valero, V., Arun, B., Royce, M., Adinin, R., Hoelzer, K., Walters, R., Wade, J.L., Pusztai, L., Hortobagyi, G.N., Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J. Clin. Oncol. 21 (2003), 3249–3254, 10.1200/JCO.2003.03.111.
24. Lammers, T., Subr, V., Ulbrich, K., Peschke, P., Huber, P.E., Hennink, W.E., Storm, G., Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 30 (2009), 3466–3475, 10.1016/j.biomaterials.2009.02.040.
25. Croissant, J.G., Zhang, D., Alsaiari, S., Lu, J., Deng, L., Tamanoi, F., Zink, J.I., Khashab, N.M., Croissant, J. et al., Protein-gold clusters-capped mesoporous silica nanoparticles for drug co-delivery and in-vivo imaging. J. Control. Release 229:2016 (2016), 183–191, 10.1016/j.jconrel.2016.03.030.
26. Mallik, S., Anajafi, T., Scott, M.D., You, S., Yang, X., Choi, Y., Qian, S.Y., Mallik, S., Acridine orange conjugated polymersomes for simultaneous nuclear delivery of gemcitabine and doxorubicin to pancreatic cancer cells. Bioconjug. Chem. 27 (2016), 762–771, 10.1021/acs.bioconjchem.5b00694.
27. Nahire, R., Haldar, M.K., Paul, S., Ambre, A.H., Meghnani, V., Layek, B., Katti, K.S., Gange, K.N., Singh, J., Sarkar, K., Mallik, S., Multifunctional polymersomes for cytosolic delivery of gemcitabine and doxorubicin to cancer cells. Biomaterials 35 (2014), 6482–6497, 10.1016/j.biomaterials.2014.04.026.
28. Liu, D., Chen, Y., Feng, X., Deng, M., Xie, G., Wang, J., Zhang, L., Liu, Q., Yuan, P., Micellar nanoparticles loaded with gemcitabine and doxorubicin showed synergistic effect. Colloids Surf. B. Biointerfaces 113 (2014), 158–168, 10.1016/j.colsurfb.2013.08.010.
29. Wang, C., Zhang, G., Liu, G., Hu, J., Liu, S., Photo- and thermo-responsive multicompartment hydrogels for synergistic delivery of gemcitabine and doxorubicin. J. Control. Release, 2016, 10.1016/j.jconrel.2016.11.007.
30. Dalla Pozza, E., Lerda, C., Costanzo, C., Donadelli, M., Dando, I., Zoratti, E., Scupoli, M.T., Beghelli, S., Scarpa, A., Fattal, E., Arpicco, S., Palmieri, M., Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity. Biochim. Biophys. Acta. 1828 (2013), 1396–1404, 10.1016/j.bbamem.2013.01.020.
31. Cho, H.J., Yoon, H.Y., Koo, H., Ko, S.H., Shim, J.S., Lee, J.H., Kim, K., Chan Kwon, I., Kim, D.D., Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic for tumor-targeted delivery of docetaxel. Biomaterials 32 (2011), 7181–7190, 10.1016/j.biomaterials.2011.06.028.
32. Song, S., Qi, H., Xu, J., Guo, P., Chen, F., Li, F., Yang, X., Sheng, N., Wu, Y., Pan, W., Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting. Pharm. Res. 31 (2014), 2988–3005, 10.1007/s11095-014-1393-4.
33. Zhong, Y., Goltsche, K., Cheng, L., Xie, F., Meng, F., Deng, C., Zhong, Z., Haag, R., Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo. Biomaterials 84 (2016), 250–261, 10.1016/j.biomaterials.2016.01.049.
34. Lee, H., Lee, K., Tae, G.P., Hyaluronic acid-paclitaxel conjugate micelles: Synthesis, characterization, and antitumor activity. Bioconjug. Chem. 19 (2008), 1319–1325, 10.1021/bc8000485.
35. Xin, D., Wang, Y., Xiang, J., The use of amino acid linkers in the conjugation of paclitaxel with hyaluronic acid as drug delivery system: synthesis, self-assembled property, drug release, and in vitro efficiency. Pharm. Res. 27 (2010), 380–389, 10.1007/s11095-009-9997-9.
36. Oommen, O.P., Garousi, J., Sloff, M., Varghese, O.P., Tailored doxorubicin-hyaluronan conjugate as a potent anticancer glyco-drug: An alternative to prodrug approach. Macromol. Biosci. 14 (2014), 327–333, 10.1002/mabi.201300383.
37. Cai, S., Thati, S., Bagby, T.R., Diab, H.M., Davies, N.M., Cohen, M.S., Forrest, M.L., Laird, M., Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer. J. Control. Release. 146 (2010), 212–218, 10.1016/j.jconrel.2010.04.006.
38. Noh, I., Kim, H.-O., Choi, J., Choi, Y., Lee, D.K., Huh, Y.-M., Haam, S., Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer. Biomaterials 53 (2015), 763–774, 10.1016/j.biomaterials.2015.03.006.
39. Dubey, R.D., Klippstein, R., Wang, J.T.-W., Hodgins, N., Mei, K.-C., Sosabowski, J., Hider, R.C., Abbate, V., Gupta, P.N., Al-Jamal, K.T., Novel Hyaluronic Acid Conjugates for Dual Nuclear Imaging and Therapy in CD44-Expressing Tumors in Mice In Vivo. Nanotheranostics 1 (2017), 59–79, 10.7150/ntno.17896.
40. Cai, S., Xie, Y., Bagby, T.R., Cohen, M.S., Forrest, M.L., Intralymphatic Chemotherapy Using a Hyaluronan-Cisplatin Conjugate. J. Surg. Res. 147 (2008), 247–252, 10.1016/j.jss.2008.02.048.
41. Camacho, K.M., Kumar, S., Menegatti, S., Vogus, D.R., Anselmo, A.C., Mitragotri, S., Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid. J. Control. Release 210 (2015), 198–207, 10.1016/j.jconrel.2015.04.031.
42. Cohen, S.M., Mukerji, R., Cai, S., Damjanov, I., Forrest, M.L., Cohen, M.S., Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo. Am. J. Surg. 202 (2011), 646–653, 10.1016/j.amjsurg.2011.06.027.
43. Chou, T.C., Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58 (2006), 621–681, 10.1124/pr.58.3.10.
44. Guo, Z.W., Gallo, J.M., Selective protection of 2′,2′-difluorodeoxycytidine (gemcitabine). J. Org. Chem. 64 (1999), 8319–8322, 10.1021/jo9911140.
45. Lin, N., Zeng, S., Ma, S., Fan, Y., Zhong, H., Fang, L., Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector 1. Acta Pharmacol. Sin. 25 (2004), 1584–1589.
46. Dasari, M., Acharya, A.P., Kim, D., Lee, S., Lee, S., Rhea, J., Molinaro, R., Murthy, N., H-Gemcitabine: a new gemcitabine prodrug for treating cancer. Bioconjug. Chem. 24 (2013), 4–8, 10.1021/bc300095m.
47. Vale, N., Ferreira, A., Fernandes, I., Alves, C., João, M., Mateus, N., Gomes, P., Bioorganic & medicinal chemistry letters gemcitabine anti-proliferative activity significantly enhanced upon conjugation with cell-penetrating peptides. Bioorg. Med. Chem. Lett. 27 (2017), 2898–2901, 10.1016/j.bmcl.2017.04.086.
48. Zhang, R.X., Wong, H.L., Xue, H.Y., Eoh, J.Y., Wu, X.Y., Nanomedicine of synergistic drug combinations for cancer therapy-strategies and perspectives. J. Control. Release 240 (2016), 489–503, 10.1016/j.jconrel.2016.06.012.
49. Richter, S.N., Cartei, G., Nadai, M., Trestin, A., Barzon, L., Palumbo, M., Palù G., In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancer. Ann. Oncol. 17 (2006), v20–v24, 10.1093/annonc/mdj944.
50. Ling, Y.H., El-Naggar, A.K., Priebe, W., Perez-Soler, R., Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol. Pharmacol. 49 (1996), 832–841.
51. Tonkinson, J.L., Worzalla, J.F., Teng, C.H., Mendelsohn, L.G., Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res. 59 (1999), 3671–3676.
52. Bar-On, O., Shapira, M., Hershko, D.D., Differential effects of doxorubicin treatment on cell cycle arrest and Skp2 expression in breast cancer cells. Anticancer Drugs 18 (2007), 1113–1121, 10.1097/CAD.0b013e3282ef4571.
53. Cappella, P., Tomasoni, D., Faretta, M., Lupi, M., Montalenti, F., Viale, F., Banzato, F., D'Incalci, M., Ubezio, P., Cell cycle effects of gemcitabine. Int. J. Cancer 93 (2001), 401–408, 10.1002/ijc.1351 (pii).
54. Baabur-Cohen, H., Vossen, L.I., Krüger, H.R., Eldar-boock, A., Yeini, E., Landa-Rouben, N., Tiram, G., Wedepohl, S., Markovsky, E., Leor, J., Calderon, M., Satchi-Fainaro, R., In vivo comparative study of distinct polymeric architectures bearing a combination of paclitaxel and doxorubicin at a synergistic ratio. J. Control. Release 257 (2017), 118–131, 10.1016/j.jconrel.2016.06.037.
55. Le, H.K., Graham, L., Cha, E., Morales, J.K., Manjili, M.H., Bear, H.D., Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int. Immunopharmacol. 9 (2009), 900–909, 10.1016/j.intimp.2009.03.015.
56. Yang, J., Zhang, R., Pan, H., Li, Y., Fang, Y., Zhang, L., Kopecek, J., Backbone degradable HPMA copolymer conjugates with gemcitabine and paclitaxel: impact of molecular weight on activity toward human ovarian carcinoma xenografts. Mol. Pharm., 2017 (acs.molpharmaceut.6b01005) http://dx.doi.org/10.1021/acs.molpharmaceut.6b01005.
57. Cai, S., Xie, Y., Davies, N.M., Cohen, M.S., Forrest, M.L., Pharmacokinetics and disposition of a localized lymphatic polymer hyaluron conjugate of cisplatin in rodents. J. Pharm. Sci. 99 (2010), 2664–2671, 10.1002/jps.22016.Pharmacokinetics.
58. Jadin, L., Bookbinder, L.H., Frost, G.I., A comprehensive model of hyaluronan turnover in the mouse. Matrix Biol. 31 (2012), 81–89, 10.1016/j.matbio.2011.11.002.
59. Saxena, M., Christofori, G., Rebuilding cancer metastasis in the mouse. Mol. Oncol. 7 (2013), 283–296, 10.1016/j.molonc.2013.02.009.
60. Duangjai, A., Luo, K., Zhou, Y., Yang, J., Kopeček, J., Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells. Eur. J. Pharm. Biopharm. 87 (2014), 187–196, 10.1016/j.ejpb.2013.11.008.
61. Zhang, R., Yang, J., Sima, M., Zhou, Y., Kopeček, J., Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 12181–12186, 10.1073/pnas.1406233111.